Thu, Oct 23, 2014, 10:43 AM EDT - U.S. Markets close in 5 hrs 17 mins

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

dinepat203 500 posts  |  Last Activity: 9 minutes ago Member since: Sep 29, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Summary

    Background
    We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever.
    Methods
    A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV.
    Findings
    Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection.

  • dinepat203 dinepat203 Oct 16, 2014 2:44 PM Flag

    BCX4430 could inhibit Ebola virus reproduction in cultured human cells with about half of its potency toward Marburg. The drug doesn’t appear to cause mutations in the DNA of cultured cells and doesn’t kill normal cells until the drug’s concentration is increased 10 to 50 times the antiviral concentration.

    The drug is classified as a nucleoside analogue, a relative of adenine, meaning that it’s small and might be stable enough to ship and stockpile where needed. It works by blocking the virus’ replication of its RNA genome by setting up a molecular road block, a process called chain termination. For context, that’s how Valtrex (valacyclovir) inhibits the DNA replication of herpes simplex viruses.

  • dinepat203 dinepat203 Oct 16, 2014 2:38 PM Flag

    BCX4430 could inhibit Ebola virus reproduction in cultured human cells with about half of its potency toward Marburg. The drug doesn’t appear to cause mutations in the DNA of cultured cells and doesn’t kill normal cells until the drug’s concentration is increased 10 to 50 times the antiviral concentration.

    The drug is classified as a nucleoside analogue, a relative of adenine, meaning that it’s small and might be stable enough to ship and stockpile where needed. It works by blocking the virus’ replication of its RNA genome by setting up a molecular road block, a process called chain termination. For context, that’s how Valtrex (valacyclovir) inhibits the DNA replication of herpes simplex viruses.

  • Reply to

    Run up to CHMP opinion on Oct 24

    by anitdua Oct 15, 2014 10:05 PM
    dinepat203 dinepat203 Oct 16, 2014 2:36 PM Flag

    SANOFI is going to manufacture and probably Market Contrave in Europe.

  • U.S. company, BioCryst Pharmaceuticals, is currently developing a drug called BCX4430 to treat a broad spectrum of viruses including Ebola, with the partial support of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

    BCX4430 has proven effective in a small study of non-human primates (cynomolgus monkeys) in preventing death from a closely-related virus called Marburg that causes the fatal symptoms shared by Ebolavirus.

    This work, published in the journal Nature earlier this year, was conducted at a biosafety level 4 facility at the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Maryland.

    Intramuscular injections of BCX4430 were able to prevent death from the Marburg virus in 6 out of 6 monkeys given the drug 1 or 24 hours after viral infection. All of the animals were alive at 30 days post-infection while all 6 control animals were dead by day 12. When given the drug 48 hours after infection, 5 of the 6 animals survived at day 30.
    While Marburg virus is not exactly Ebola, it behaves similarly in humans. The researchers did show that BCX4430 could inhibit Ebola virus reproduction in cultured human cells with about half of its potency toward Marburg. The drug doesn’t appear to cause mutations in the DNA of cultured cells and doesn’t kill normal cells until the drug’s concentration is increased 10 to 50 times the antiviral concentration.

    The drug is classified as a nucleoside analogue, a relative of adenine, meaning that it’s small and might be stable enough to ship and stockpile where needed. It works by blocking the virus’ replication of its RNA genome by setting up a molecular road block, a process called chain termination. For context, that’s how Valtrex (valacyclovir) inhibits the DNA replication of herpes simplex viruses.

  • dinepat203 dinepat203 Oct 16, 2014 1:58 PM Flag

    NLNK 23% NOW

  • Reply to

    Cash In Now

    by gjsmith128 Oct 16, 2014 1:11 PM
    dinepat203 dinepat203 Oct 16, 2014 1:23 PM Flag

    $10 PLUS.....

  • An NDA for BioCryst’s influenza drug, permavir, is currently under review by FDA, with a PDUFA action date of December 23, 2014

  • dinepat203 dinepat203 Oct 16, 2014 12:47 PM Flag

    The company employees 41 across both facilities. An NDA for BioCryst’s influenza drug, permavir, is currently under review by FDA, with a PDUFA action date of December 23, 2014.

  • U.S. company, BioCryst Pharmaceuticals, is currently developing a drug called BCX4430 to treat a broad spectrum of viruses including Ebola, with the partial support of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

    BCX4430 has proven effective in a small study of non-human primates (cynomolgus monkeys) in preventing death from a closely-related virus called Marburg that causes the fatal symptoms shared by Ebolavirus.

    This work, published in the journal Nature earlier this year, was conducted at a biosafety level 4 facility at the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Maryland.

    Intramuscular injections of BCX4430 were able to prevent death from the Marburg virus in 6 out of 6 monkeys given the drug 1 or 24 hours after viral infection. All of the animals were alive at 30 days post-infection while all 6 control animals were dead by day 12. When given the drug 48 hours after infection, 5 of the 6 animals survived at day 30.

    Awaiting human testing

    While Marburg virus is not exactly Ebola, it behaves similarly in humans. The researchers did show that BCX4430 could inhibit Ebola virus reproduction in cultured human cells with about half of its potency toward Marburg. The drug doesn’t appear to cause mutations in the DNA of cultured cells and doesn’t kill normal cells until the drug’s concentration is increased 10 to 50 times the antiviral concentration.

    The drug is classified as a nucleoside analogue, a relative of adenine, meaning that it’s small and might be stable enough to ship and stockpile where needed. It works by blocking the virus’ replication of its RNA genome by setting up a molecular road block, a process called chain termination. For context, that’s how Valtrex (valacyclovir) inhibits the DNA replication of herpes simplex viruses.

  • The most advanced trials are the front-line Glioblastoma, and Breast cancer. Both though are expected to have huge value in the future, because they are expected to be multi billion dollar drugs in the biotech world. The company has already proven itself without outstanding phase 2 results, but remember phase 3 is the riskiest phases of all.

  • Reply to

    Shenzi, did you cover your short yet

    by jd39souza98 Oct 15, 2014 9:55 PM
    dinepat203 dinepat203 Oct 16, 2014 12:18 PM Flag

    $5 ON THE WAY

  • 24 OCT OUT But Earlier this year the EMA agreed to the filing in advance of the Light Study interim analysis ... It seems positive feedback from Europe's EMA regarding the anti-obesity pill Contrave.

  • dinepat203 dinepat203 Oct 16, 2014 10:12 AM Flag

    Ebola worries Wall Street

  • NIH Offers Update on Progress of Ebola Treatments and Vaccines
    While it is not possible at this time to determine whether ZMapp benefited these patients, NIAID is supporting a broader effort to advance development and clinical testing of ZMapp to determine if it is safe and effective....
    NIAID is also supporting the development of other potential treatments. Among them is BCX4430, a drug that BioCryst Pharmaceuticals (Nasdaq: BCRX)

  • dinepat203 dinepat203 Oct 15, 2014 5:48 PM Flag

    How much is your house worth? Take leverage only for limits available with your house worth otherwise time is for start covering your short position before too late.

  • dinepat203 dinepat203 Oct 15, 2014 3:21 PM Flag

    NO VVUS......NO ARNA ...But only OREX has $190 Million Cash before Launch + Royalties..

  • Reply to

    OREX NOW CROSSING $4

    by dinepat203 Oct 15, 2014 2:55 PM
    dinepat203 dinepat203 Oct 15, 2014 3:19 PM Flag

    $1190Million Cash in Books ....=$10

  • Reply to

    Contrave $212.87, Generic Contrave $55.83

    by sauve9 Oct 15, 2014 3:12 PM
    dinepat203 dinepat203 Oct 15, 2014 3:18 PM Flag

    BUT SHARES OF OREX IS $10 CAUSE $190 MILLION CASH

AEGR
32.69+1.29(+4.11%)10:43 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.